Microporous bilayer osmotic tablet for colon-specific delivery

Chaudhary, Anurag; Tiwari, Neha; Jain, Vikas; Singh, Ranjit

doi:10.1016/j.ejpb.2011.01.004

Cited by 54 publications

(25 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment of IBD and local delivery of NSAID can be done using nanoparticle matrices that have been engineered to favourably collapse within the targeted area, taking advantage of specific characteristics of the inflamed colon, such as pH [139], release of oxidative species [140] and osmotic systems [141]. Moreover, biomaterials such as hydrogels have biological, physical, and chemical characteristics that make them major candidates for nanoparticles vectorization.…”

Section: Nanocarriersmentioning

confidence: 99%

Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs

Serpe¹,

Canaparo²,

Foglietta³

et al. 2013

CPD

View full text Add to dashboard Cite

Pharmaceutical technology has introduced a promising pathway in the future of medicinein particular nanotechnological innovations have provided the opportunity to design and develop efficient drug delivery systems able to target and treat several diseases, including those mediated by inflammation. The engineering of drug delivery systems can be used to target tissues involved in the pathology under treatment, to avoid early drug biological environmental degradation and to modulate drug pharmacokinetics. Glucocorticoids and non-steroidal anti-inflammatory drugs are the most commonly prescribed drug categories worldwide for the treatment of disorders associated with inflammation.Although glucocorticoids can be highly effective in treating inflammation, their systemic application is limited due to the high incidence of serious adverse effects, mainly in long-term treatment. Non-steroidal anti-inflammatory drugs are a heterogeneous group of compounds and most of them have unfavorable pharmacokinetics and pharmacodynamics, leading to adverse effects, such as gastrointestinal disorders. Therefore, the need for drug delivery systems for long term administration of anti-inflammatory drugs witha well-controlled release profile is evident. The aim of this review is to assess innovative colloidal drugs carriers, in particular liposomes and nanoparticles, with special focus on site-specific delivery for particularly problematic tissues such as the gastrointestinal tract, joints and eyes.3

show abstract

Section: Nanocarriersmentioning

confidence: 99%

Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs

Serpe¹,

Canaparo²,

Foglietta³

et al. 2013

CPD

View full text Add to dashboard Cite

show abstract

“…Stability studies were conducted for F3 floating tablets using ICH guidelines i.e., stored at 40 ± 2°C and 75 ± 5% RH in the humidity chamber for six months [22]. Then the collected samples were determined for assay and in vitro dissolution rate and statistically analysed using paired t-test at 0.05 significance level [23].…”

Section: Stability Studiesmentioning

confidence: 99%

Formulation and Pharmacokinetics of Ketorolac Tromethamine Floating Compression Coated Mini-Tablets

Sk¹,

Rk²,

Veerareddy³

2017

J Bioequiv Availab

View full text Add to dashboard Cite

“…Three replicates of F4 formulation tablets were sealed in apolyethylene pack with inside aluminum coating and stored at 40±2°C and 75±5% RH in the humidity chamber for 6 months (19). Specimens were collected following 6 months of storage and determined the drug content and in vitro dissolution rate (20).…”

Section: Stability Studiesmentioning

confidence: 99%

A Novel Approach to Flurbiprofen Pulsatile Colonic Release: Formulation and Pharmacokinetics of Double-Compression-Coated Mini-Tablets

Vemula

2015

AAPS PharmSciTech

View full text Add to dashboard Cite

Abstract. A significant plan is executed in the present study to study the effect of double-compression coating on flurbiprofen core mini-tablets to achieve the pulsatile colonic delivery to deliver the drug at a specific time as per the patho-physiological need of the disease that results in improved therapeutic efficacy. In this study, pulsatile double-compression-coated tablets were prepared based on timecontrolled hydroxypropyl methylcellulose K100M inner compression coat and pH-sensitive Eudragit S100 outer compression coat. Then, the tablets were evaluated for both physical evaluation and drugrelease studies, and to prove these results, in vivo pharmacokinetic studies in human volunteers were conducted. From the in vitro drug-release studies, F6 tablets were considered as the best formulation, which retarded the drug release in the stomach and small intestine (3.42±0.12% in 5 h) and progressively released to the colon (99.78±0.74% in 24 h). The release process followed zero-order release kinetics, and from the stability studies, similarity factor between dissolution data before and after storage was found to be 88.86. From the pharmacokinetic evaluation, core mini-tablets producing peak plasma concentration (C max ) was 14,677.51±12.16 ng/ml at 3 h T max and pulsatile colonic tablets showed C max =12,374.67± 16.72 ng/ml at 12 h T max . The area under the curve for the mini and pulsatile tablets was 41,238.52 and 72,369.24 ng-h/ml, and the mean resident time was 3.43 and 10.61 h, respectively. In conclusion, development of double-compression-coated tablets is a promising way to achieve the pulsatile colonic release of flurbiprofen.

show abstract

Microporous bilayer osmotic tablet for colon-specific delivery

Cited by 54 publications

References 15 publications

Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs

Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs

Formulation and Pharmacokinetics of Ketorolac Tromethamine Floating Compression Coated Mini-Tablets

A Novel Approach to Flurbiprofen Pulsatile Colonic Release: Formulation and Pharmacokinetics of Double-Compression-Coated Mini-Tablets

Contact Info

Product

Resources

About